Compare AJANTA PHARMA with Lupin - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AJANTA PHARMA vs LUPIN - Comparison Results

LUPIN 
   Change

Lupin is a leading pharmaceutical company with a strong presence in anti-infective, cardiovascular and asthma. Apart from having a strong domestic presence, the company markets its products in the regulated markets of the US and Europe and semi-regul... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    AJANTA PHARMA LUPIN AJANTA PHARMA/
LUPIN
 
P/E (TTM) x 24.4 41.5 58.8% View Chart
P/BV x 6.8 3.8 177.6% View Chart
Dividend Yield % 0.5 0.6 91.6%  

Financials

 AJANTA PHARMA   LUPIN
EQUITY SHARE DATA
    AJANTA PHARMA
Mar-19
LUPIN
Mar-20
AJANTA PHARMA/
LUPIN
5-Yr Chart
Click to enlarge
High Rs1,422882 161.2%   
Low Rs898505 177.7%   
Sales per share (Unadj.) Rs233.5339.4 68.8%  
Earnings per share (Unadj.) Rs44.0-5.9 -739.3%  
Cash flow per share (Unadj.) Rs52.215.5 337.1%  
Dividends per share (Unadj.) Rs9.006.00 150.0%  
Dividend yield (eoy) %0.80.9 89.7%  
Book value per share (Unadj.) Rs255.1276.7 92.2%  
Shares outstanding (eoy) m88.02453.00 19.4%   
Bonus/Rights/Conversions BBESOP-  
Price / Sales ratio x5.02.0 243.0%   
Avg P/E ratio x26.4-116.6 -22.6%  
P/CF ratio (eoy) x22.244.8 49.6%  
Price / Book Value ratio x4.52.5 181.4%  
Dividend payout %20.5-100.9 -20.3%   
Avg Mkt Cap Rs m102,081314,201 32.5%   
No. of employees `0006.818.3 37.2%   
Total wages/salary Rs m4,30729,868 14.4%   
Avg. sales/employee Rs Th3,022.68,400.6 36.0%   
Avg. wages/employee Rs Th633.41,632.0 38.8%   
Avg. net profit/employee Rs Th569.1-147.2 -386.6%   
INCOME DATA
Net Sales Rs m20,554153,748 13.4%  
Other income Rs m2114,838 4.4%   
Total revenues Rs m20,765158,585 13.1%   
Gross profit Rs m5,66424,849 22.8%  
Depreciation Rs m7219,702 7.4%   
Interest Rs m123,630 0.3%   
Profit before tax Rs m5,14316,355 31.4%   
Minority Interest Rs m04 0.0%   
Prior Period Items Rs m039 0.0%   
Extraordinary Inc (Exp) Rs m0-7,521 0.0%   
Tax Rs m1,27311,571 11.0%   
Profit after tax Rs m3,870-2,694 -143.6%  
Gross profit margin %27.616.2 170.5%  
Effective tax rate %24.870.8 35.0%   
Net profit margin %18.8-1.8 -1,074.5%  
BALANCE SHEET DATA
Current assets Rs m11,812154,132 7.7%   
Current liabilities Rs m3,77692,252 4.1%   
Net working cap to sales %39.140.2 97.1%  
Current ratio x3.11.7 187.2%  
Inventory Days Days7782 94.3%  
Debtors Days Days82129 63.1%  
Net fixed assets Rs m14,39889,082 16.2%   
Share capital Rs m175906 19.4%   
"Free" reserves Rs m22,277124,461 17.9%   
Net worth Rs m22,452125,367 17.9%   
Long term debt Rs m717,933 0.0%   
Total assets Rs m26,962249,839 10.8%  
Interest coverage x444.35.5 8,070.6%   
Debt to equity ratio x00.1 0.2%  
Sales to assets ratio x0.80.6 123.9%   
Return on assets %14.40.4 3,842.9%  
Return on equity %17.2-2.1 -802.1%  
Return on capital %23.08.7 263.0%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m10,68251,450 20.8%   
Fx outflow Rs m2,10219,470 10.8%   
Net fx Rs m8,58031,980 26.8%   
CASH FLOW
From Operations Rs m3,74814,688 25.5%  
From Investments Rs m-2,22811,070 -20.1%  
From Financial Activity Rs m-1,475-8,906 16.6%  
Net Cashflow Rs m4516,853 0.3%  

Share Holding

Indian Promoters % 73.8 46.6 158.4%  
Foreign collaborators % 0.0 0.2 -  
Indian inst/Mut Fund % 1.6 11.3 13.7%  
FIIs % 7.6 31.9 23.8%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.0 10.1 168.3%  
Shareholders   20,968 98,259 21.3%  
Pledged promoter(s) holding % 4.4 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare AJANTA PHARMA With:   VENUS REMEDIES  SHASUN PHARMA  PFIZER  J.B.CHEMICALS  NEULAND LABS  

Compare AJANTA PHARMA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends Flat; Wipro & Hindalco Industries Among Top Nifty Gainers(Closing)

Indian share markets witnessed volatile trading activity throughout the day today and ended on a flat note.

Related Views on News

AJANTA PHARMA Announces Quarterly Results (3QFY21); Net Profit Up 64.2% (Quarterly Result Update)

Feb 5, 2021 | Updated on Feb 5, 2021

For the quarter ended December 2020, AJANTA PHARMA has posted a net profit of Rs 2 bn (up 64.2% YoY). Sales on the other hand came in at Rs 7 bn (up 15.0% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.

LUPIN 2019-20 Annual Report Analysis (Annual Result Update)

Dec 7, 2020 | Updated on Dec 7, 2020

Here's an analysis of the annual report of LUPIN for 2019-20. It includes a full income statement, balance sheet and cash flow analysis of LUPIN. Also includes updates on the valuation of LUPIN.

AJANTA PHARMA Announces Quarterly Results (2QFY21); Net Profit Up 46.3% (Quarterly Result Update)

Nov 6, 2020 | Updated on Nov 6, 2020

For the quarter ended September 2020, AJANTA PHARMA has posted a net profit of Rs 2 bn (up 46.3% YoY). Sales on the other hand came in at Rs 7 bn (up 11.4% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.

LUPIN Announces Quarterly Results (2QFY21); Net Profit Up 271.3% (Quarterly Result Update)

Nov 6, 2020 | Updated on Nov 6, 2020

For the quarter ended September 2020, LUPIN has posted a net profit of Rs 2 bn (up 271.3% YoY). Sales on the other hand came in at Rs 38 bn (down 12.0% YoY). Read on for a complete analysis of LUPIN's quarterly results.

AJANTA PHARMA Announces Quarterly Results (1QFY21); Net Profit Up 28.9% (Quarterly Result Update)

Aug 24, 2020 | Updated on Aug 24, 2020

For the quarter ended June 2020, AJANTA PHARMA has posted a net profit of Rs 1 bn (up 28.9% YoY). Sales on the other hand came in at Rs 7 bn (up 9.2% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.

More Views on News

Most Popular

India: Recovery Stalled by Vaccine Games?(The Honest Truth)

Apr 13, 2021

Ajit Dayal on how India's vaccine strategy will impact the markets.

4 Stocks to Make Your Portfolio Immune to the Second Covid Wave(Profit Hunter)

Apr 6, 2021

Rather than predicting the market, successful investing is more about preparing well and placing your bets accordingly.

An India Revival Stock I'm Bullish On...(Profit Hunter)

Apr 9, 2021

This could take India to the position of 3rd largest economy.

Why Did the Market Crash on Monday?(Fast Profits Daily)

Apr 13, 2021

In this video, I'll you what I think is the real reason behind yesterday's market crash.

A Unique Sector for Short-Term Profits(Fast Profits Daily)

Apr 12, 2021

This ignored sector could deliver big short-term profits.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

AJANTA PHARMA SHARE PRICE


Apr 16, 2021 (Close)

TRACK AJANTA PHARMA

  • Track your investment in AJANTA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

AJANTA PHARMA - STERLING BIOTECH COMPARISON

COMPARE AJANTA PHARMA WITH

MARKET STATS